Novocure’s Optune Now Available at More Than 360 Cancer Treatment Centers in the U.S.
Globally, more than 500 medical institutions can prescribe Optune to glioblastoma patients ST. HELIER, Jersey–(BUSINESS WIRE)–Physicians at more than 360 cancer treatment centers in the U.S. have been certified to prescribe Novocure’s (NASDAQ:NVCR) Optune to newly diagnosed and recurrent glioblastoma (GBM) patients. Physicians at an additional 140 medical institutions throughout the world also can prescribe …